KOSDAQBiotech & Pharma311690

CJ Bioscience

₩3,415▼ 2.29%2026-11-18 close
Market Cap
₩44.6B
Turnover
₩15,901,690
Volume
4.7K
Shares out.
13.1M
PER
—
PBR
1.2×
EPS
-₩1,627
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses narrowing, but pipeline proof still pending

CJ Bioscience recorded operating losses in each year from 2022 through 2025, and its operating loss in the third quarter of 2026 narrowed from a year earlier, yet revenue remains too small for its drug and wellness projects to show up meaningfully in reported results.

  1. 1

    Revenue in 2025 was KRW 3.69 billion against an operating loss of KRW 24.8 billion, an operating margin of -671.2%. The small revenue base makes the ratio look extreme.

  2. 2

    The 2025 operating loss of KRW 24.8 billion was smaller than the KRW 34.2 billion recorded in 2024, and the third-quarter 2026 operating loss of KRW 4.93 billion narrowed year on year.

  3. 3

    The second-quarter 2026 operating loss widened to KRW 6.4 billion before narrowing in the third quarter, so the quarterly trend has not settled in one direction.

  4. 4

    The debt-to-equity ratio was 34.9% at the end of 2025, down from 84.0% in 2022, with total equity of KRW 53.6 billion and total liabilities of KRW 18.7 billion.

  5. 5

    The CJRB-101, CJRB-201 and CJRB-302 pipeline and the planned second-half 2026 launch of a customized MAC solution are the next points to watch.

02

Business structure

CJ Bioscience has been a subsidiary of CJ CheilJedang since its acquisition in 2021, and it is building two businesses around microbiome technology: drug development and wellness.

Its drug pipeline comprises CJRB-101, a candidate for lung and head-and-neck cancer in combination with Keytruda, CJRB-201, a candidate for inflammatory bowel disease (IBD), and CJRB-302, a candidate for Parkinson's disease.

CJRB-201 is built on beneficial bacteria found naturally in the gut of healthy people, and anti-inflammatory data in a chronic colitis mouse model were presented at a conference in June 2026.

The core of the wellness side is MACPLAN, a personalized nutrition brand based on gut-microbiota-accessible carbohydrates, designed with an in-house gut simulation system and AI.

A human study of four MAC formulations in 210 adults and an AI model predicting product responders from gut microbial patterns were presented as the evidence base.

The gut microbiome testing service Gut Inside is expanding through agreements with medical institutions including Korean medicine hospitals and nursing hospitals. Customers are pharmaceutical companies that may license drug candidates in the drug segment, and consumers and medical institutions in the wellness segment.

In June 2024 the company announced a vision to achieve three technology export deals by 2026. No segment revenue breakdown is available from the public data reviewed, and with revenue this small the weight of the business still sits in research and development.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩700M-₩6.1B−823.7%
2025Q4₩1.3B-₩5.2B−410.0%
2026Q1₩800M-₩5.3B−682.2%
2026Q2₩900M-₩6.4B−712.5%
2026Q3₩900M-₩4.9B−571.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩4.1B-₩33.2B-₩34.9B−815.6%−70.3%84.0%
2023₩5.6B-₩32.1B-₩22.9B−575.0%−32.0%27.5%
2024₩3.5B-₩34.2B-₩32.8B−987.8%−42.2%28.1%
2025₩3.7B-₩24.8B-₩24B−671.2%−44.8%34.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a reported basis, revenue rose from KRW 4.07 billion in 2022 to KRW 5.58 billion in 2023, up 36.8% year on year, which was the largest year of 2022 to 2025. It fell to KRW 3.47 billion in 2024, down 37.8% year on year and the smallest year, and recovered slightly to KRW 3.69 billion in 2025, up 6.5% year on year.

Operating losses were KRW 33.2 billion in 2022, KRW 32.1 billion in 2023, KRW 34.2 billion in 2024 and KRW 24.8 billion in 2025, which is four consecutive years of losses. The loss narrowed in 2023, widened in 2024 when revenue fell, and narrowed again in 2025.

Operating margins were -815.6% in 2022, -575.0% in 2023, -987.8% in 2024 and -671.2% in 2025, so the ratio was most negative in the year revenue was smallest.

Net loss attributable to controlling shareholders was KRW 34.9 billion in 2022, KRW 22.9 billion in 2023, KRW 32.8 billion in 2024 and KRW 24 billion in 2025, and net loss including non-controlling interests was reported at the same yearly amounts.

Operating cash flow was negative in every year, at -KRW 21 billion in 2022, -KRW 24.9 billion in 2023, -KRW 27.8 billion in 2024 and -KRW 23.4 billion in 2025. The debt-to-equity ratio moved from 84.0% in 2022 to 27.5% in 2023, 28.1% in 2024 and 34.9% in 2025.

Total equity at the end of 2025 was KRW 53.6 billion, all attributable to controlling shareholders, against total liabilities of KRW 18.7 billion.

By quarter, revenue jumped to KRW 1.26 billion in the fourth quarter of 2025, up 70.5% from the prior quarter, then fell to KRW 783 million in the first quarter of 2026, rose to KRW 898 million in the second quarter and was KRW 863 million in the third quarter.

The operating loss widened from KRW 6.08 billion in the third quarter of 2025 to KRW 6.4 billion in the second quarter of 2026 before narrowing to KRW 4.93 billion in the third quarter.

Net loss attributable to controlling shareholders over the last four quarters, from the fourth quarter of 2025 to the third quarter of 2026, totaled KRW 21.3 billion.

A 2024 press report put ordinary R&D spending at KRW 18.9 billion in 2022 and KRW 22.5 billion in 2023, with KRW 15.6 billion spent through the third quarter of 2024, so a large share of the losses is tied to pipeline research.

05

Industry analysis

The microbiome field is one where drug developers and food and health-supplement companies are moving in parallel, as efforts grow to use gut microbes as drug targets or nutrition solutions.

On the drug side, inflammatory bowel disease is widely linked to pathological changes in gut microbes, which is why CJRB-201 draws attention. The data currently public are at the mouse-model and preclinical stage.

On the wellness side, personalized nutrition services that combine diet and gut microbiome data are being discussed as a new market, and the company is building evidence for MACPLAN through academic channels such as the Korean Society of Food Science and Nutrition.

At a meeting in late October 2026, the company reported that a Korea-specific diet index showed clinical-marker associations exceeding existing diet indices.

Unlike large Korean biotech companies that earn revenue from manufacturing or commercial products, CJ Bioscience is an early-stage company with a thin revenue base. Among listed companies in the same sector, its profile is more concentrated in the pipeline-validation stage.

Gut microbiome testing depends on distribution through hospitals and health checkup channels, so expansion of such agreements can shape the pace of the business. Competitors include microbiome drug developers in Korea and abroad as well as food companies that have entered the gut-health market.

06

Outlook

The nearest checkpoint the company has set out is the commercialization and market launch of its customized MAC solution in the second half of 2026. In a June 2026 announcement, the company said the launch would be based on results from its human application study.

In the same announcement it also disclosed plans to extend its wellness business through a clinical study aimed at reducing side effects of obesity treatments.

On the drug side, the development strategy and preclinical data for CJRB-201 for IBD were presented at a June 2026 industry session, and the next step will be whether it enters follow-on clinical testing. The target of three technology export deals by 2026, announced in June 2024, has a deadline of December 31, 2026.

Technology export deals surface through contract disclosures with partner pharmaceutical companies, so whether such disclosures appear around the deadline will show whether the target was met.

In a 2024 response to an inquiry from exchange authorities, parent company CJ CheilJedang said it was reviewing various strategic options for its biotech business, so funding for research and the business structure could change depending on the parent's decisions.

A press report also argued that R&D spending is likely to rise as development advances. Ahead, the fourth-quarter 2026 preliminary results and the 2026 annual report are the next checkpoints, and the full-year 2026 operating loss confirmed in the annual report will be the benchmark for judging the loss trend.

07

Valuation

PER
—
PBR
1.2×
ROE
-43.8%
EPS
-₩1,627
BPS
₩2,901
Dividend per share
₩0

Valuation is hard to read through earnings-based metrics. Because the company has posted net losses attributable to controlling shareholders over the last four quarters, its price-to-earnings ratio cannot be calculated.

Its price-to-book ratio, a net-asset-based measure, sits slightly above 1, which means the premium to total equity is modest. With no dividend payment history, a comparison of dividend yield with listed peers carries little meaning.

How the valuation is read depends on whether the weight is placed on current net assets or on the trend of narrowing losses.

Losses have narrowed since 2025, which widens the room for earnings-based metrics to emerge, but the second quarter of 2026 saw losses widen again, so the quarterly trend needs to be watched alongside.

Set against listed biotech and pharmaceutical companies that earn revenue and profit in the same sector, the company's value depends heavily on how far its pipeline results can go, so a comparison of net assets alone cannot fully explain it.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Narrower losses across recent years

The 2025 operating loss of KRW 24.8 billion was smaller than the KRW 34.2 billion in 2024. The third-quarter 2026 operating loss of KRW 4.93 billion also narrowed year on year and was below the KRW 6.4 billion of the prior quarter.

Revenue reached KRW 1.26 billion in the fourth quarter of 2025 and KRW 863 million in the third quarter of 2026, which is higher than a year earlier. Whether the narrowing came from revenue growth or cost control needs to be settled from line-item breakdowns.

Lower leverage on the balance sheet

The debt-to-equity ratio fell from 84.0% in 2022 to 34.9% in 2025. Total liabilities were KRW 18.7 billion and total equity was KRW 53.6 billion at the end of 2025, all of it attributable to controlling shareholders. Operating cash outflows continued every year, however, so equity is being consumed as losses accumulate.

Clearer timing for wellness commercialization

In June 2026 the company said it planned to commercialize and launch a customized MAC solution in the second half of 2026. Supporting data include a human study in 210 adults and an AI model predicting product responders with an ROC-AUC of 0.85.

At a late-October 2026 academic meeting, it added evidence on diet and the microbiome through poster and oral presentations. Whether wellness revenue appears in quarterly results will become clear after the launch.

09

Bear factors

Four straight years of operating losses and cash outflows

Operating losses continued for four consecutive years from 2022 through 2025, and operating cash flow was negative in all four years, ranging from -KRW 21 billion to -KRW 23.4 billion. Net loss attributable to controlling shareholders over the last four quarters totaled KRW 21.3 billion.

Quarterly losses have run for five consecutive quarters since the third quarter of 2025, so the losses have not stopped. The timing of a return to profit is hard to gauge from the current data.

Thin revenue base

Revenue of KRW 3.69 billion in 2025 is very small compared with the KRW 24.8 billion operating loss in the same year. Third-quarter 2026 revenue of KRW 863 million fell 4.0% from the prior quarter. In the second quarter of 2026, the operating loss widened to KRW 6.4 billion even with revenue of KRW 898 million. How much technology fee or wellness revenue accumulates will determine whether the revenue base strengthens.

Clinical risk and research spending burden

Ordinary R&D spending rose from KRW 18.9 billion in 2022 to KRW 22.5 billion in 2023, with KRW 15.6 billion spent through the third quarter of 2024 according to a 2024 press report. Dailypharm noted that spending will inevitably increase as development advances.

Preclinical data for CJRB-201 were released in June 2026, but whether those results lead to clinical success will be decided in later stages.

10

Risk factors

Funding

Operating cash outflows of around KRW 20 billion or more each year could require outside funding if the pipeline expands. Total equity was KRW 53.6 billion at the end of 2025, and at the current loss pace, capital will keep being consumed. The method and scale of any financing will need to be checked in future disclosures.

Clinical and technology

Validation data for the pipeline are currently centered on mouse models and preclinical studies. A newspaper headline reported that the company halted a cancer drug clinical trial and shifted toward a profitability strategy, which could change pipeline priorities. The efficacy and regulatory handling of wellness products will also need evaluation after launch.

Parent company strategy

In a 2024 response to an exchange inquiry, CJ CheilJedang said it was reviewing various strategic options for its biotech business. Research funding rose sharply after the 2021 acquisition, but a change in the parent's support or restructuring direction could affect research plans. CJ CheilJedang also runs its own biotech operations separately from CJ Bioscience.

11

What to watch next

  1. By late December 2026 (second half of 2026)

    Whether the customized MAC solution is commercialized and launched. If the launch is confirmed, the next check is how much wellness revenue appears in quarterly results.

  2. December 31, 2026

    Deadline for the target of three technology export deals by 2026, announced in 2024. Contract disclosures with partner pharmaceutical companies will show whether the target was met.

  3. During the first quarter of 2027 (timing of fourth-quarter 2026 preliminary results)

    Fourth-quarter 2026 preliminary results. These are unaudited figures before the periodic report, so they should be checked against the annual report later.

  4. End of March 2027 (statutory deadline for the annual report)

    The 2026 annual report, which will confirm full-year 2026 operating loss and operating cash flow and serve as the next reported baseline.

12

Overall view

CJ Bioscience is an early-stage biotech whose reported results show revenue of KRW 3.69 billion and an operating loss of KRW 24.8 billion in 2025.

It has recorded operating losses for four consecutive years from 2022 through 2025, the 2025 operating loss was smaller than in 2024, and the third-quarter 2026 operating loss also narrowed from a year earlier. The debt-to-equity ratio fell to 34.9% at the end of 2025, but operating cash outflows continued every year.

The bullish points are the narrowing losses, the easing of balance-sheet pressure and the planned second-half 2026 launch of wellness products. The bearish points are the thin revenue base, the burden of R&D spending and the clinical uncertainty of the pipeline.

Among the CJRB-101, CJRB-201 and CJRB-302 candidates, CJRB-201 has only mouse-model data public, so clinical-stage results are not yet reflected in reported figures. Net loss attributable to controlling shareholders over the last four quarters totaled KRW 21.3 billion, so losses have not stopped.

Because no earnings-based multiple can be calculated and the price-to-book ratio sits slightly above 1, how the valuation is read depends on whether the weight falls on net asset value or on the pace of loss reduction.

The next checkpoints are the second-half 2026 product launch, the December 31, 2026 deadline for the technology export target and the 2026 annual report due by the end of March 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. cjnews.cj.net
  2. k-health.com
  3. view.asiae.co.kr
  4. cjbioscience.com
  5. view.asiae.co.kr
  6. m.dailypharm.com
  7. newspim.com
  8. k-health.com
  9. news1.kr
  10. fnnews.com
  11. view.asiae.co.kr
  12. m.news.nate.com
  13. m.news.nate.com
  14. news1.kr
  15. hankyung.com
  16. supple.kr
  17. finomy.com
  18. judal.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis